128 related articles for article (PubMed ID: 1680941)
21. An immunoenzymometric assay for a CA125-like antigen, CA602.
Mochizuki H; Sato I; Nagoya K; Furusako S; Yamauchi T; Masuko H; Sato H; Morishita H; Yajima M; Sasaki H
J Clin Lab Anal; 1992; 6(2):84-90. PubMed ID: 1383480
[TBL] [Abstract][Full Text] [Related]
22. [Cancer-associated carbohydrate antigens available for serum diagnosis].
Sawabu N; Takemori Y; Satomura Y; Watanabe H; Kawakami H; Hattori N
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):1091-101. PubMed ID: 2898921
[TBL] [Abstract][Full Text] [Related]
23. Clinical usefulness of serum sialyl SSEA-1 antigen levels in patients with epithelial ovarian cancer. Comparative effectiveness of sialyl SSEA-1 and CA 125.
Kobayashi H; Kawashima Y
Gynecol Obstet Invest; 1990; 30(1):52-8. PubMed ID: 1977666
[TBL] [Abstract][Full Text] [Related]
24. [Determination of various tumor markers, with special reference to sialyl SSEA-1 antigen in lung cancer].
Satoh H; Yano H; Naitoh T; Takahashi N; Suyama T; Murayama J; Kameyama M; Fukuda K; Satoh T; Ohtsuka M
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2917-22. PubMed ID: 2902833
[TBL] [Abstract][Full Text] [Related]
25. [The clinical significance of serum sialyl SSEA-1 antigen in obstetrical and gynecological patients].
Tanaka T; Iwasaka T; Hayashi Y; Hachisuga T; Yokoyama M; Ohkuma Y; Matsuo N; Fukuda K; Sugimori H
Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1157-61. PubMed ID: 1975831
[TBL] [Abstract][Full Text] [Related]
26. [The significance of CA-50, SLX and ST-439 in lung cancer].
Hayasaka S; Takada M; Shinohara T; Imamura S; Takifuji N; Kudoh S; Matsui K; Kusunoki Y; Masuda N; Negoro S
Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Jul; 29(7):802-7. PubMed ID: 1681128
[TBL] [Abstract][Full Text] [Related]
27. Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers.
Kobayashi H; Ohi H; Fujii T; Terao T
Br J Cancer; 1993 Feb; 67(2):237-43. PubMed ID: 7679280
[TBL] [Abstract][Full Text] [Related]
28. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
[TBL] [Abstract][Full Text] [Related]
29. A case of thymic cyst with elevated sialylated Lewis X-i, carbohydrate antigen 19-9 and tissue polypeptide antigen in the cystic fluid with no elevation of serum tumor markers.
Sano T; Kuramochi S; Takahashi M; Asanuma F; Yamada Y; Uesato K; Toyoda H; Miyagawa T; Kurokawa T; Kawamura E
Jpn J Clin Oncol; 1991 Oct; 21(5):388-93. PubMed ID: 1684390
[TBL] [Abstract][Full Text] [Related]
30. [Development of highly sensitive enzyme immunoassay to measure urinary beta-core fragment in patients with gynecological cancer].
Nishimura R; Kobayashi K; Katsuno M; Kobayashi T
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):143-8. PubMed ID: 1690253
[TBL] [Abstract][Full Text] [Related]
31. [A fundamental and clinical investigation of cancer antigen 130 (CA 130) in the field of obstetrics and gynecology].
Inaba N; Okajima Y; Ota Y; Fukazawa I; Yamaguchi T; Sato N; Sudo H; Milanga M; Takamizawa H; Fujii S
Nihon Gan Chiryo Gakkai Shi; 1989 Oct; 24(10):2426-35. PubMed ID: 2614181
[TBL] [Abstract][Full Text] [Related]
32. Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.
Cole LA; Nam JH
Yale J Biol Med; 1989; 62(4):367-78. PubMed ID: 2596125
[TBL] [Abstract][Full Text] [Related]
33. [Diagnosis of ovarian tumor by measuring tumor markers].
Fukatsu T; Nakashima N; Takeuchi J
Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
[TBL] [Abstract][Full Text] [Related]
34. [Clinical evaluation of serum sialyl SSEA-1 (SLX) in diagnosis of cancers].
Kawakami H; Sawabu N; Takemori Y; Okai T; Motoo Y; Satomura Y; Ohta H; Watanabe H; Matsuda N; Yamakawa O
Nihon Shokakibyo Gakkai Zasshi; 1989 May; 86(5):1141-8. PubMed ID: 2571740
[TBL] [Abstract][Full Text] [Related]
35. [Heterogeneity of the CA125 antigen that coexpresses sialyl Tn and CA19-9 antigens].
Kobayashi H; Ohi H; Shinohara H; Terao T
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Sep; 45(9):980-6. PubMed ID: 8371024
[TBL] [Abstract][Full Text] [Related]
36. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
[TBL] [Abstract][Full Text] [Related]
37. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
[TBL] [Abstract][Full Text] [Related]
38. Serum placental alkaline phosphatase (PLAP) in gynecologic malignancies--with special reference to the combination of PLAP and CA54/61 assay.
Nozawa S; Udagawa Y; Ohkura H; Negishi Y; Akiya K; Inaba N; Takamizawa H; Kimura E; Terashima Y
Clin Chim Acta; 1990 Jan; 186(2):275-84. PubMed ID: 2178810
[TBL] [Abstract][Full Text] [Related]
39. Efficient screening for ovarian cancers using a combination of tumor markers CA602 and CA546.
Saito M; Aoki D; Susumu N; Suzuki A; Suzuki N; Udagawa Y; Nozawa S
Int J Gynecol Cancer; 2005; 15(1):37-44. PubMed ID: 15670295
[TBL] [Abstract][Full Text] [Related]
40. CA54/61 as a marker for epithelial ovarian cancer.
Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
